Tyra Biosciences reported Phase 2 data for dabogratinib in bladder cancer and said it will advance toward a pivotal study. The report frames the dataset as a step toward challenging established approaches in low-risk bladder cancer. Despite the clinical progress, the initial readout also drew market scrutiny tied to the reported efficacy levels relative to expectations, underscoring how Phase 2 targets can drive both next-step trial design and investor sentiment.